---
title: "Evaxion releases transcript of Q2 2026 business update and financial results call"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296607804.md"
description: "Evaxion released its Q2 2026 financial results and business update. The company reported a net loss of USD 3.7 million and held USD 14 million in cash, with runway extending into H2 2027. Management highlighted strong EVX-01 melanoma data, including a 75% overall response rate, and announced an upcoming ESMO presentation. Additionally, Evaxion introduced the preclinical EVX-05 glioblastoma vaccine developed with Duke University."
datetime: "2026-08-21T10:58:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296607804.md)
  - [en](https://longbridge.com/en/news/296607804.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296607804.md)
generator: "portal-rs"
---

# Evaxion releases transcript of Q2 2026 business update and financial results call

-   Evaxion discussed its Q2 2026 business update and financial results on Aug. 20, led by CEO Helen Tayton-Martin, CSO/COO Birgitte Rono, CFO Thomas Schmidt. \* Management set an October ESMO presentation for three-year Phase 2 EVX-01 melanoma data, including standalone vaccine and anti-PD-1 combination outcomes. \* Earlier EVX-01 readouts cited 75% overall response rate, 25% complete responses, 92% still in response; 86% vaccine targets triggered tumor-specific responses. \* Introduced preclinical EVX-05 glioblastoma off-the-shelf vaccine with Duke; target discovery completed, 16 ERV fragments selected from about 1.5 million. \* Cash was USD 14 million at quarter-end; net loss USD 3.7 million; runway reiterated into H2 2027, supported by an ATM facility. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original content used to generate this news brief on August 20, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [EVAX.US](https://longbridge.com/en/quote/EVAX.US.md)

## Related News & Research

- [Evaxion Q2 FY26 net loss narrows to USD 3.7 million; revenue posts no revenue](https://longbridge.com/en/news/296483064.md)
- [Evaxion Biotech Boosts Share Capital With August 2026 ATM ADS Offering](https://longbridge.com/en/news/298032014.md)
- [Tractor Supply declares R$ 0.05 per-unit dividend for Q3 2026](https://longbridge.com/en/news/298615733.md)
- [Southern Co announces dividend of R$ 2.62 per unit for Q3 2026 BDRs](https://longbridge.com/en/news/298615033.md)
- [Inter Parfums announces availability of 2026 half-year report](https://longbridge.com/en/news/298413126.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**